Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq climbs over 1% as SpaceX, Super Micro improve AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
Cara Therapeutics (CARA) Misses Q4 EPS by 24c
March 6, 2023 4:05 PM ESTCara Therapeutics (NASDAQ: CARA) reported Q4 EPS of ($0.56), $0.24 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $3.3 million versus the consensus estimate of $14.54 million.
For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.
... More


